TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded TriSalus Life Sciences from a "sell" to a "hold"; the stock's consensus from three analysts is an average rating of Hold with an average target price of $7.00, even as Canaccord cut its price target from $12 to $7 while keeping a buy rating.
• TriSalus slightly beat Q4 expectations (EPS ($0.12) vs. ($0.13) est., revenue $13.21M vs. $13.20M) and reaffirmed FY2026 revenue guidance of $60M–$62M while expanding its PEDD portfolio, signaling modest operational momentum.
• The stock opened at $4.47 (one‑year range $3.42–$7.95) with a market cap of about $224M and a negative P/E (‑2.44); institutional ownership is low (~2.6%) with several funds modestly increasing stakes recently.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

A number of other equities analysts have also commented on the stock. Canaccord Genuity Group reduced their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a "buy" rating on the stock in a research report on Friday. Weiss Ratings reiterated a "sell (e+)" rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Finally, Zacks Research upgraded TriSalus Life Sciences from a "strong sell" rating to a "hold" rating in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of "Hold" and an average target price of $7.00.

TriSalus Life Sciences Stock Performance

TLSI opened at $4.47 on Friday. The stock's 50 day moving average price is $5.36 and its 200-day moving average price is $5.36. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $7.95. The stock has a market cap of $223.77 million, a price-to-earnings ratio of -2.44 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.20 million. As a group, analysts predict that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Large investors have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in shares of TriSalus Life Sciences by 1.8% during the second quarter. Bank of America Corp DE now owns 188,906 shares of the company's stock valued at $1,030,000 after purchasing an additional 3,374 shares in the last quarter. Connective Capital Management LLC raised its stake in TriSalus Life Sciences by 12.8% in the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company's stock worth $179,000 after buying an additional 3,717 shares in the last quarter. Millennium Management LLC lifted its holdings in TriSalus Life Sciences by 17.7% during the third quarter. Millennium Management LLC now owns 35,612 shares of the company's stock worth $166,000 after buying an additional 5,359 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in TriSalus Life Sciences during the second quarter worth $29,000. Finally, JPMorgan Chase & Co. boosted its position in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after acquiring an additional 7,519 shares in the last quarter. Institutional investors own 2.58% of the company's stock.

More TriSalus Life Sciences News

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Q4 results slightly beat expectations — TLSI reported ($0.12) EPS vs. a ($0.13) consensus and revenue of $13.21M vs. $13.20M expected, a small but constructive beat that supports near‑term operational momentum. Earnings Call Highlights
• Positive Sentiment: Company reaffirmed FY2026 revenue guidance of $60M–$62M and said it is expanding its PEDD portfolio — guidance above Street revenue consensus may support longer‑term growth expectations. Guidance & PEDD Expansion
• Positive Sentiment: Brokerage support remains: Lake Street reaffirmed its buy stance, keeping institutional endorsement visible to investors. Lake Street Rating
• Neutral Sentiment: Full earnings call transcripts and coverage are available (useful for detail but not new headline items) — investors can review management commentary on growth initiatives and margins. Earnings Call Transcript
• Neutral Sentiment: Independent estimates and models updated by firms such as Northland provide refreshed forecasts but contain no single consensus surprise; these are reference points for investors modeling FY2026. Northland Estimates
• Negative Sentiment: Canaccord cut its price target from $12 to $7 while keeping a buy rating — the sizable downgrade in upside reduces some analyst‑driven upside expectations and likely pressured the stock despite the buy rating. Canaccord Price Target Cut

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.